Company / Current Liabilities
Corbus Pharmaceuticals Holdings, Inc. Current Liabilities History
FY2015-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$12.6M
FY2022
5-year range
$12.6M / $34.9M
FY2018-FY2022
Trend
-25.7%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Liabilities has declined for 3 consecutive years, from $35M in FY2019 to $13M in FY2022.
Based on SEC 10-K filings.
$13M in FY2022 with a 5-year CAGR of +9.0%.
Improved from $32M to $13M over the past 2 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -28.7%
- 5-Year CAGR
- +9.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- Corbus Pharmaceuticals Holdings, Inc.'s current liabilities has declined for 3 consecutive years.
- 5-year CAGR of +9.0%, indicating consistent growth.
- In FY2022, current liabilities decreased 25.7% year-over-year.
- Peak current liabilities was recorded in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -12.48 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $12.6M | -25.7% |
| FY2021 | $17.0M | -46.7% |
| FY2020 | $31.9M | -8.6% |
| FY2019 | $34.9M | +92.9% |
| FY2018 | $18.1M | +120.5% |
| FY2017 | $8.2M | -7.8% |
| FY2016 | $8.9M | +145.1% |
| FY2015 | $3.6M | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026